Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Docket Number (Optional) TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING "REFERENCE" APPLICATION 05432/100M919-US4 In re Application of: Connie Sanchez et al. Application No.: 10/644,587-Conf. #5266 Filed: August 20, 2003 THE USE OF ENANTIOMERIC PURE ESCITALOPRAM H. Lundbeck A/S percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of any patent granted on pending reference Application Number 10/644.588 , filed on August 20, 2003 as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the reference application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on said reference application, "as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application," in the event that: any such patent: granted on the pending reference application: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant. Check either box 1 or 2 below, if appropriate. For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, 1. etc.), the undersigned is empowered to act on behalf of the business/organization. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. The undersigned is an attorney or agent of records Reg. No. November 15, 2006 Signature Date Jay P. Lessler Typed or printed name (212) 527-7765 Telephone Number Terminal disclaimer fee under 37 CFR 1.20(d) is included. *Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this statement. See MPEP § 324.

PTO/SB/25 (09-06)
Approved for use through 03/31/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING	Docket Number (Optional)
REJECTION OVER A PENDING "REFERENCE" APPLICATION	05432/100M919-US4
In re Application of: Connie Sanchez et al.	
Application No.: 10/644,587-Conf. #5266	
Filed: August 20, 2003	
riled. Adgust 20, 2005	
For: THE USE OF ENANTIOMERIC PURE ESCITALOPRAM	
The owner*, H. Lundbeck A/S	, of 100
percent interest in the instant application hereby disclaims, except as provided below, the termi	inal part of the statutory term of
any patent granted on the instant application which would extend beyond the expiration date of patent granted on pending reference Application Number 10/468,685 filed on	June 8, 2004
as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patent granted on	said reference application may
be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending ref	
hereby agrees that any patent so granted on the instant application shall be enforceable only for and any patent granted on the reference application are commonly owned. This agreement r	
the instant application and is binding upon the grantee, its successors or assigns.	bilo mini any patent grantos an
In making the above disclaimer, the owner does not disclaim the terminal part of any	patent granted on the instant
application that would extend to the expiration date of the full statutory term as defined in 35 U.	S.C. 154 and 173 of any patent
granted on said reference application, "as the term of any patent granted on said reference ap any terminal disclaimer filed prior to the grant of any patent on the pending reference applicati	
any terminal disclaimer filed prior to the grant of any patent on the pending reference applicationatents. Detention the pending reference applications expires for failure to pay a maintenance	
ound invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or termin	nally disclaimed under 37 CFR
1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner te of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.	minated prior to the expiration
, , , , , , , , , , , , , , , , , , , ,	
Check either box 1 or 2 below, if appropriate.	
1. For submissions on behalf of a business/organization (e.g., corporation, partnership,	, university, government agency
etc.), the undersigned is empowered to act on behalf of the business/organization.	
I hereby declare that all statements made herein of my own knowledge are true and information and belief are believed to be true; and further that these statements were made with	
statements and the like so made are punishable by fine or imprisonment, or both, under Section	
States Code and that such willful false statements may jeopardize the validity of the application or	any patent issued thereon.
2. X The undersigned is an attorney or Agent of record. Ref No. 41.151	
2. X The undersigned is an attorney or agent of record. Reg No. 41,151	
$\bigvee_{r \in \mathcal{I}} \mathcal{I}^r \bigvee_{r \in \mathcal{I}}$	November 15, 2006
Signature	Date
' [
Jay P. Lessler	
Typed or printed name	(040) 507 7765
	(212) 527-7765 Telephone Number
	Total Training
X Terminal disclaimer fee under 37 CFR 1.20(d) is included.	
``	
Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (or	vner).
Form PTO/SB/96 may be used for making this statement. See MPEP § 324.	

PTO/SB/98 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)	
Applicant/Patent Owner: Connie Sanchez et al.	
Application No./Patent No.: 10/644,587 Filed/Issue Date: August 20, 2003	
Entitled: THE USE OF ENANTIOMERIC PURE ESCITALOPRAM	
H. Lundbeck A/S , a Corporation (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)	
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)	
states that it is:	
1. the assignee of the entire right, title, and interest; or	
2. x an assignee of less than the entire right, title and interest.	
(The extent (by percentage) of its ownership interest is100%)	
in the patent application/patent identified above by virtue of either:	
An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 014714 Frame 0158 , or a true copy of the original assignment is attached.	
OR	
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:	
1. From: To:	
The document was recorded in the United States Patent and Trademark Office at	
Reel , Frame , or for which a copy thereof is attached.	
2. From: To:	
The document was recorded in the United States Patent and Trademark Office at	
Reel , Frame , or for which a copy thereof is attached.	
3. From: To:	
The document was recorded in the United States Patent and Trademark Office at	
Reel, Frame, or for which a copy thereof is attached.	
Additional documents in the chain of title are listed on a supplemental sheet.	
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO.	
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.	
November 15, 2006	
Signature Date	
Jay P. Lessler (212) 527-7765	
Printed or Typed Name Telephone Number	
Attorney of Record	
Title	